MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Country |
 USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
103 M |
Market Cap[1] |
$ 249 M |
EBITDA (LTM) |
$ -196 M |
P/E (LTM) |
- |
P/S (LTM) |
4.58 |
EPS (LTM) |
-1.86 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.76 | 2.03 % | $ 790 M | Nasdaq Global Select Market |  Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 3.39 | 0.89 % | $ 262 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 212.95 | 1.33 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
Aptorum Group Limited
APM
|
$ 1.28 | -3.76 % | $ 6.98 M | Nasdaq Global Select Market |  China |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.39 | -0.88 % | $ 8.16 B | Nasdaq Capital Market |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 89.67 | -0.69 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.58 | -1.24 % | $ 1.24 B | Nasdaq Global Select Market | USA |
 |
Anika Therapeutics
ANIK
|
$ 9.58 | 0.95 % | $ 140 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Biogen
BIIB
|
$ 174.16 | 0.96 % | $ 25.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Aytu BioScience
AYTU
|
$ 2.32 | 1.84 % | $ 14.6 M | Nasdaq Capital Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.69 | -2.08 % | $ 522 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 95.45 | -0.58 % | $ 27.2 B | Nasdaq Global Select Market |  Germany |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 573.81 | -1.24 % | $ 43.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.28 | -2.62 % | $ 609 M | NYSE American | Israel |
 |
Catalyst Biosciences
CBIO
|
$ 15.24 | -0.46 % | $ 1 B | Nasdaq Capital Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
BioVie
BIVI
|
$ 1.49 | -1.57 % | $ 2.2 M | Nasdaq Capital Market | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.81 | -0.47 % | $ 1.79 M | Nasdaq Global Select Market | USA |
 |
Cellectar Biosciences
CLRB
|
$ 3.7 | -2.08 % | $ 45.2 M | Nasdaq Capital Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.52 | 0.7 % | $ 745 M | NYSE | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
- | -5.68 % | $ 8.28 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | USA |
 |
Cerus Corporation
CERS
|
$ 2.23 | 3.49 % | $ 412 M | Nasdaq Global Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.